{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:53:47Z","timestamp":1781880827601,"version":"3.54.5"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,25]]},"abstract":"<jats:p>In order to evaluate the short-term outcomes of switching to faricimab from other anti-vascular endothelial growth factor (VEGF) agents in Chinese patients with neovascular age-related macular degeneration (nAMD). This was a retrospective, observational study involving patients with nAMD who had insufficient response to previous anti-VEGF therapy and were switched to Faricimab. Best-corrected visual acuity, central macular thickness, and pigment epithelium detachment (PED) changes were recorded at baseline and after one month of treatment. Data were analyzed using paired t-tests to compare outcomes before and after the switch. This study included 35 eyes from 35 patients (mean age 69.74\u2005\u00b1\u200511.22 years) who were switched to Faricimab after an average of 6.27\u2005\u00b1\u20053.41 prior anti-VEGF injections for nAMD. While best-corrected visual acuity showed no significant improvement after one month (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.06), significant reductions were observed in mean central macular thickness (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001), PED height (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001), PED volume (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001), presence of subretinal fluid (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.03), and intraretinal fluid (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.04). Additionally, the presence of PED decreased from 60% at baseline to 45.71% after one month (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.02). No new safety concerns were identified during the study period. Switching to faricimab from other anti-VEGF agents resulted in significant short-term improvements in both visual and anatomical outcomes, including reduced central macular thickness, pigment epithelium detachment, and subretinal and intraretinal fluid. These findings suggest that Faricimab may offer a beneficial alternative for patients with an insufficient response to prior anti-VEGF therapies. Long-term follow-up studies are necessary to confirm the durability and long-term benefits of this treatment.<\/jats:p>","DOI":"10.1097\/md.0000000000042002","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T23:01:13Z","timestamp":1745881273000},"page":"e42002","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Short-term comparison of switching to faricimab from other anti-VEGF agents in neovascular age-related macular degeneration patients: A retrospective study"],"prefix":"10.1097","volume":"104","author":[{"given":"Dingxi","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, The Third People\u2019s Hospital of Dalian, Dalian Medical University, Dalian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Third People\u2019s Hospital of Dalian, Dalian Medical University, Dalian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Third People\u2019s Hospital of Dalian, Dalian Medical University, Dalian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Third People\u2019s Hospital of Dalian, Dalian Medical University, Dalian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250904","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy.","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch Ophthalmol (Chicago, IL: 1960)"},{"key":"R2-20250904","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/jcm11020325","article-title":"Managing neovascular age-related macular degeneration in clinical practice: systematic review, meta-analysis, and meta-regression.","volume":"11","author":"Veritti","year":"2022","journal-title":"J Clin Med"},{"key":"R3-20250904","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.survophthal.2020.05.003","article-title":"Influence of pigment epithelial detachment on visual acuity in neovascular age-related macular degeneration.","volume":"66","author":"Cheong","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"R4-20250904","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2165\/00003495-200868080-00002","article-title":"Neovascular age-related macular degeneration: potential therapies.","volume":"68","author":"Chappelow","year":"2008","journal-title":"Drugs"},{"key":"R5-20250904","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R6-20250904","doi-asserted-by":"crossref","first-page":"100906","DOI":"10.1016\/j.preteyeres.2020.100906","article-title":"Incomplete response to Anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities.","volume":"82","author":"Mettu","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"R7-20250904","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/biom14030252","article-title":"Treatment strategies for anti-VEGF resistance in neovascular age-related macular degeneration by targeting arteriolar choroidal neovascularization.","volume":"14","author":"Fu","year":"2024","journal-title":"Biomolecules"},{"key":"R8-20250904","first-page":"193","article-title":"Real-world data on faricimab switching in treatment-refractory neovascular age-related macular degeneration.","volume":"14","author":"Ng","year":"2024","journal-title":"Life (Basel, Switzerland)"},{"key":"R9-20250904","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s40123-024-00980-5","article-title":"Real-world outcomes of a loading phase with intravitreal faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME).","volume":"13","author":"Giancipoli","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"R10-20250904","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3390\/medicina60071170","article-title":"Short-term comparison of switching to brolucizumab or faricimab from aflibercept in neovascular AMD patients.","volume":"60","author":"Kin","year":"2024","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"R11-20250904","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"R12-20250904","doi-asserted-by":"crossref","first-page":"100076","DOI":"10.1016\/j.xops.2021.100076","article-title":"TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration.","volume":"1","author":"Khanani","year":"2021","journal-title":"Ophthalmol Sci"},{"key":"R13-20250904","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s00417-024-06421-0","article-title":"Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration.","volume":"262","author":"Schneider","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R14-20250904","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","article-title":"Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab.","volume":"8","author":"Raimondi","year":"2024","journal-title":"Ophthalmol. Retina"},{"key":"R15-20250904","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","article-title":"Short-term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy.","volume":"8","author":"Szigiato","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"R16-20250904","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s40123-023-00779-w","article-title":"Visual and anatomical outcomes after initial intravitreal faricimab injection for neovascular age-related macular degeneration in patients with prior treatment history.","volume":"12","author":"Inoda","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"R17-20250904","doi-asserted-by":"crossref","first-page":"1192464","DOI":"10.3389\/fncel.2023.1192464","article-title":"Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia\/reperfusion.","volume":"17","author":"Canonica","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"R18-20250904","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/s41433-020-0803-6","article-title":"The relationship between pigment epithelial detachment and visual outcome in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.","volume":"34","author":"Cheong","year":"2020","journal-title":"Eye (London, England)"},{"key":"R19-20250904","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2.","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:04:48Z","timestamp":1756987488000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":19,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042002","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]}}}